Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage therapeutics - VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.
Company profile
Ticker
KTRA
Exchange
Website
CEO
Saiid Zarrabian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Berry Only Inc., DelMar Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Del Mar Pharmaceuticals (BC) Ltd. • 0959454 B.C. Ltd. • 0959456 B.C. Ltd. • Adgero Biopharmaceuticals Holdings, Inc. • Adgero Biopharmaceuticals, Inc. ...
IRS number
990360497
KTRA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
17 May 24
DEF 14A
Definitive proxy
17 May 24
425
Business combination disclosure
14 May 24
8-K
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
14 May 24
10-Q
2024 Q3
Quarterly report
14 May 24
S-4
Registration of securities issued in business combination transactions
13 May 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9 May 24
8-K
Regulation FD Disclosure
25 Apr 24
425
Business combination disclosure
25 Apr 24
425
Business combination disclosure
3 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm |
Cash burn (monthly) | (no burn) | (no burn) | 670.33 k | 776.92 k | 766.67 k | 603.50 k |
Cash used (since last report) | n/a | n/a | 1.17 mm | 1.36 mm | 1.34 mm | 1.05 mm |
Cash remaining | n/a | n/a | 5.18 mm | 5.00 mm | 5.01 mm | 5.30 mm |
Runway (months of cash) | n/a | n/a | 7.7 | 6.4 | 6.5 | 8.8 |
Institutional ownership, Q2 2023
3.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 140.76 mm |
Total shares | 2.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pilkiewicz Carolyn | 1.15 mm | $587.00 k |
Intracoastal Capital | 900.13 k | $1.15 mm |
Lind Global Fund II | 75.47 k | $0.00 |
Geode Capital Management | 14.04 k | $56.57 mm |
STT State Street | 10.72 k | $43.21 mm |
Acadian Asset Management | 6.48 k | $25.00 k |
Tower Research Capital | 4.78 k | $19.25 mm |
MS Morgan Stanley | 3.35 k | $13.48 mm |
Advisor | 981.00 | $3.97 mm |
JPM JPMorgan Chase & Co. | 559.00 | $2.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Aug 23 | Johnson Laura L. | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Tamara A Seymour | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Hoffman Robert | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 23,142 | 107.73 k | 23,142 |
30 Aug 23 | Toth Robert Joseph JR | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Brown Dennis M | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 10,175 | 47.36 k | 10,175 |
News
12 Health Care Stocks Moving In Monday's Pre-Market Session
20 May 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
17 May 24
12 Health Care Stocks Moving In Thursday's After-Market Session
16 May 24
Kintara Therapeutics Q3 2024 GAAP EPS $(0.05)
14 May 24
12 Health Care Stocks Moving In Friday's After-Market Session
26 Apr 24
Press releases
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
14 May 24
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates NVEI, CHX, KTRA, ABIO
27 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
11 Apr 24
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
9 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRA
8 Apr 24